What Is Retatrutide?
Retatrutide (LY3437943) is an investigational triple receptor agonist developed by Eli Lilly. Unlike semaglutide (GLP-1 receptor only) or tirzepatide (GLP-1 + GIP), retatrutide activates three receptors simultaneously:
- GLP-1 receptor (glucagon-like peptide-1)
- GIP receptor (glucose-dependent insulinotropic polypeptide)
- Glucagon receptor (unique to retatrutide)
As of April 2026, retatrutide remains in Phase 3 clinical trials and is not yet FDA approved. However, Phase 2 data has positioned it as a significant research compound with unprecedented efficacy in body weight reduction.
The Triple Agonist Mechanism: Why It Matters
The three-receptor activation profile creates a distinct pharmacological signature compared to dual-agonist compounds like tirzepatide.
GLP-1 Receptor Activation
The GLP-1 receptor is the foundation of this drug class. GLP-1 activation reduces appetite, slows gastric emptying, and improves insulin sensitivity. This is the mechanism shared by semaglutide, tirzepatide, and retatrutide.
GIP Receptor Activation
GIP (glucose-dependent insulinotropic polypeptide) enhances insulin secretion in response to nutrient intake. When combined with GLP-1 in tirzepatide, GIP activation provided superior weight loss to semaglutide alone. The GIP component also appears to reduce nausea—a common side effect of GLP-1 monotherapy.
Glucagon Receptor Activation
This is retatrutide's unique distinction. Glucagon receptor activation does two critical things:
- Drives hepatic glucose output: The glucagon receptor controls the liver's release of glucose into the bloodstream. This counterintuitively improves metabolic control when combined with insulin-enhancing GLP-1/GIP.
- Increases energy expenditure via lipolysis: Glucagon activation directly stimulates fat oxidation (fat burning). This is not appetite suppression—it's metabolic acceleration. This explains why retatrutide shows particularly dramatic fat mass reduction, not just total weight loss.
Clinical Evidence: Phase 2 and Current Trials
Phase 2 Trial Results
The landmark Phase 2 trial (published in New England Journal of Medicine, 2023) tested retatrutide across multiple dose tiers over 24 weeks:
- Primary finding: Body weight reduction up to 24% in the highest-dose group (15mg weekly)
- Comparison context: This exceeds semaglutide Phase 2 results (~15%) and tirzepatide Phase 2 results (~22%)
- Onset: Significant weight loss visible by week 4–6
- Body composition: Lean body mass preservation was observed—the drug reduces fat preferentially
Safety Profile
The most common adverse events in Phase 2 were gastrointestinal:
- Nausea (dose-dependent, mild to moderate severity)
- Vomiting (less frequent than nausea)
- Diarrhea (variable)
Critically, the frequency and severity of these events were comparable to tirzepatide and semaglutide. No new, unexpected safety signals were identified. Cardiovascular safety monitoring is ongoing in Phase 3.
Phase 3 Trials (TRIUMPH Series)
Four Phase 3 trials are underway as of April 2026:
- TRIUMPH-1: Primary obesity trial, randomized, placebo-controlled
- TRIUMPH-2: Type 2 diabetes (T2DM) cohort
- TRIUMPH-3: Cardiovascular outcomes trial
- TRIUMPH-4: Comparison arm (likely vs. tirzepatide or semaglutide)
Results from TRIUMPH-1 and TRIUMPH-2 are expected by late 2026. Cardiovascular outcomes (TRIUMPH-3) will take longer—potentially 2027–2028.
Retatrutide vs. Tirzepatide vs. Semaglutide
A comprehensive comparison reveals how these three compounds fit into the GLP-1 landscape:
| Property | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor Targets | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Approval Status | Approved (Ozempic, Wegovy) | Approved (Mounjaro, Zepbound) | Phase 3 (2026) |
| Clinical Weight Loss (Phase 2/3) | ~15% | ~22% | ~24% (Phase 2) |
| Unique Mechanism | Appetite suppression + insulin | Dual incretin + appetite | Triple agonist + direct lipolysis |
| Peptide Complexity | Long-chain amide | Complex GIP/GLP chimera | Complex triple-chimera |
| Half-Life | ~7 days | ~5 days | ~6 days (est.) |
Research Applications and Purity Considerations
Retatrutide is a complex synthetic peptide requiring exceptional structural integrity. The three-receptor selectivity depends entirely on precise amino acid sequencing and post-translational modification.
Purity Requirements
For meaningful research, retatrutide must meet these minimum standards:
- HPLC purity: ≥99% — High-performance liquid chromatography confirms the main compound and quantifies impurities
- LC-MS identity confirmation: Mandatory — Mass spectrometry proves the molecular weight is correct and matches the expected structure
- Endotoxin testing (LAL): ≤1 EU/mL — Gram-negative bacterial contamination can confound research results
Why Purity Matters
Any structural deviation—missing amino acids, wrong stereochemistry, oxidation, or dimer formation—will shift receptor binding profiles. This invalidates research results. A retatrutide sample at 96% purity might show entirely different receptor selectivity than a 99% pure sample because the impurities preferentially affect glucagon vs. GLP-1 binding.
Current Research Landscape
Clinical Research
Most retatrutide research is conducted by Eli Lilly as part of the TRIUMPH trial series. Academic research has been limited due to the compound's investigational status, though pre-publication data is occasionally presented at major conferences (ADA, ASPC, ENDO).
Pre-Clinical Model Research
Several independent research groups are investigating:
- Glucagon receptor contribution to lipolysis: Does the glucagon component provide additive fat-loss benefit beyond GLP-1/GIP, or is it synergistic?
- Metabolic disease models: Comparing triple vs. dual vs. single agonist approaches in rodent obesity/diabetes models
- Receptor selectivity: Understanding why retatrutide shows the receptor balance it does, and whether alternative dosing ratios might improve tolerability
Future Directions
After FDA approval (estimated 2027–2028), research will likely focus on:
- Long-term cardiovascular safety outcomes
- Combination therapies (retatrutide + other metabolic agents)
- Body composition outcomes (lean vs. fat mass preservation)
- Adaptation and tolerance over years of continuous use
How to Source Research-Grade Retatrutide
Given retatrutide's complexity and investigational status, sourcing is more restricted than approved compounds. At Lone Star Peptide Co., we maintain the highest purity standards:
- HPLC ≥99% confirmed by independent lab analysis
- LC-MS identity verification included in every batch
- COA documentation with full purity, identity, and endotoxin data
- Storage and handling guidance specific to retatrutide's stability profile
Always request and review the Certificate of Analysis before use. For retatrutide, this is non-negotiable.